1111 GMT - U.S. President Trump's plans for 25% tariffs on pharmaceutical imports could threaten the European sector, which relies heavily on the U.S. Swiss pharma giant Roche said it is closely monitoring U.S. legislative developments and assessing any potential impact these could have on its business. The company invested over 11 billion Swiss francs ($12.18 billion) in the U.S. over the last ten years and remains committed to invest there, the company added. GSK's chief executive officer Emma Walmsley said in a media call alongside results that the company will keep a close eye on how the fast-moving tariff situation will play out in the coming weeks. The British pharma company employs around 15000 people in the U.S. and has various R&D centres and manufacturing sites across the country. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 19, 2025 06:12 ET (11:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。